Detailed Narrative
Q1 FY26 Financial Performance Overview
Divi's Laboratories reported a consolidated total income of ₹2,529 crores for Q1 FY26, marking a 15.11% year-on-year growth from ₹2,197 crores in Q1 FY25. Profit After Tax (PAT) saw a significant increase of 26.74% YoY, reaching ₹545 crores compared to ₹430 crores in the prior year. The company also recorded a forex gain of ₹39 crores in the current quarter, a turnaround from a ₹1 crore loss in Q1 FY25, contributing to the improved profitability.
Strategic Initiatives: Custom Synthesis & Peptide Synthesis
Custom Synthesis continues to be a core growth engine, with a healthy pipeline of RFPs and active projects expected to transition to commercial scale within 12 to 24 months. The company has expanded its scientific capabilities, particularly in Solid Phase Peptide Synthesis, which has garnered strong interest from large pharmaceutical companies for GLP-1-based treatments. However, commercialization timelines for peptide products have been revised to 18-24 months, subject to regulatory approvals and innovator timelines.
Kakinada Unit 3 and Backward Integration
The Unit 3 facility in Kakinada, operational since January 2025, is strategically focused on producing key starting materials and intermediates, reinforcing self-sufficiency and strengthening the overall value chain. This unit is playing a critical role in freeing up GMP capacity in existing Units 1 and 2 by moving critical starting material production. While Unit 3 is contributing meaningfully to production, regulatory approvals for new products in this facility are expected to take 1 to 2 years, delaying full commercial potential.
Market Dynamics: Generics Pricing and Geopolitical Impact
The generic business continues to face persistent pricing pressures, a trend observed over the last few quarters, compounded by geopolitical situations and increased logistical costs, such as those related to the Red Sea problem. Management expressed hope for stabilization in pricing over the next few quarters. The product mix for generics to custom synthesis stood at 47% and 53% respectively for the quarter, with management preferring a 50:50 split for the full year.
Capital Expenditure and Liquidity Position
Divi's Laboratories anticipates a total capital expenditure of ₹2,000 crores for FY26, directed towards strategic projects, capacity expansion, and technology upgrades across its operations. In Q1 FY26, assets worth ₹261 crores were capitalized, with ₹114 crores specifically allocated for Kakinada Phase 1. The company maintains a strong liquidity position, reporting ₹4,205 crores in cash on books, alongside ₹2,521 crores in receivables and ₹3,087 crores in inventory at the end of the quarter.
Nutraceutical Business and New Generic Product Pipeline
The global nutraceutical business demonstrated robust growth, increasing 40.45% YoY to ₹250 crores in Q1 FY26 from ₹178 crores in Q1 FY25, reflecting a steady rise in this segment. The company also has a pipeline of new generic products, including Brivaracetam and Ticagrelor, for which DMFs have been filed and validations completed. Management expects to see commercial volumes for these new products within the next 6 to 12 months, pending customer approvals.